Wiley adds new titles in several categories to its lineup

Share this article:
Wiley adds new titles in several categories to its lineup
Wiley adds new titles in several categories to its lineup

Wiley's 2013 is looking like an expansive year. The publisher announced in March that it will enter 2014 with at least 66 new titles under its umbrella, 52 of which were snapped up from other publishers or were self-published.

The new titles span several categories including scientific, medical and scholarly research and education. Among the new journals are former Nature pub Obesity, which Wiley has been publishing since the first of the year. Wiley landed the title through a tendering process that began two years ago. Clinical Pharmacology in Drug Development and the Journal of Clinical Pharmacology came over from Sage; the titles are packaged as a two-for-one, with a subscription base of around 500 institutions.

The formerly self-published Journal of the Experimental Analysis of Behavior (612 institutional subscribers) and Journal of Applied Behavior Analysis (1,006 institutional subscriptions) joined up after a 2012 bidding process. Wiley's first JEAB issue went out in January, and JABA hit its Wiley milestone this month.

Wiley's acquisition mode also includes open-access titles. The company has confirmed 10 new open-access titles for 2013, including Physiological Reports and Immunity, Inflammation and Disease, and expects to add three more titles this year, which would bring its open-access titles to around 25. The pipeline isn't all rehashes: among the new-to-market titles is Stat, an “online-only rapid communication research journal.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.